Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Free Cash Flow (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Free Cash Flow data on record, last reported at -$15.2 million in Q3 2025.

  • For Q3 2025, Free Cash Flow changed 0.45% year-over-year to -$15.2 million; the TTM value through Sep 2025 reached -$55.8 million, down 344.24%, while the annual FY2024 figure was -$51.1 million, 327.43% down from the prior year.
  • Free Cash Flow reached -$15.2 million in Q3 2025 per ASMB's latest filing, up from -$16.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $73.6 million in Q4 2023 and bottomed at -$36.4 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$14.0 million, with a median of -$18.4 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 277.36% in 2021, then soared 482.13% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$19.4 million in 2021, then grew by 0.65% to -$19.3 million in 2022, then skyrocketed by 482.13% to $73.6 million in 2023, then crashed by 100.55% to -$407000.0 in 2024, then plummeted by 3628.5% to -$15.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$15.2 million in Q3 2025, -$16.8 million in Q2 2025, and -$23.4 million in Q1 2025.